More than 60 percent of lung cancer patients who received Pfizer (PFE.N) Inc’s crizotinib in an early stage clinical trial were still alive after two years, according to data released on Wednesday.
While the drug was not compared to other medicines or placebo -- a higher standard of clinical trial -- the results marked the first overall survival data from the closely watched Pfizer drug.
